4.5 Article

Genotoxicity and neonatal subchronic toxicity assessment of a novel mixture of the human-identical milk oligosaccharides lacto-N-fucopentaose I and 2′-fucosyllactose

Journal

JOURNAL OF APPLIED TOXICOLOGY
Volume 41, Issue 4, Pages 632-649

Publisher

WILEY
DOI: 10.1002/jat.4071

Keywords

2 '-fucosyllactose; food ingredient; genotoxicity; human milk oligosaccharide; human-identical milk oligosaccharide; infant formula; lacto-N-fucopentaose I; neonatal; safety; subchronic toxicity

Categories

Ask authors/readers for more resources

Human milk oligosaccharides (HMOs) are bioactive molecules found in human breast milk, with potential applications in infant formula. The safety assessment of LNFP-I/2'-FL, a human-identical milk oligosaccharide, showed it to be non-genotoxic and safe for use in food products.
Human milk oligosaccharides (HMOs) are a complex group of bioactive molecules largely observed in human breast milk but also occurring in limited amounts in other mammalian milks. Advances in biotechnology have enabled production of human-identical milk oligosaccharides (HiMOs), structurally identical molecules to HMOs found naturally in human milk, intended for addition to infant formula to more closely replicate breast milk. Biosynthesis of a novel mixture of two major HMOs, lacto-N-fucopentaose I and 2 '-fucosyllactose (LNFP-I/2 '-FL), recently became possible. To support the safety of LNFP-I/2 '-FL for use in infant formula and other foods, it was subject to a safety assessment comprising a bacterial reverse mutation test, anin vitromammalian cell micronucleus test, and a 90-day oral gavage study in neonatal rats. In the 90-day study (the first HiMO study to include the new endocrine-sensitive endpoints described in the 2018 version of OECD Test Guideline 408), LNFP-I/2 '-FL was administered by oral gavage to neonatal rats once daily (from Day 7 of age) for 90 consecutive days, at doses up to 5000 mg/kg bw/day, followed by a 4-week recovery period. Concurrent reference controls received 5000 mg/kg bw/day of the approved infant formula ingredient oligofructose. LNFP-I/2 '-FL was nongenotoxicin vitro. The highest dose tested (5000 mg/kg bw/day) was established as the no-observed-adverse-effect level in the 90-day study, as there were no test article-related adverse effects on clinical observations, body weight, food consumption, clinical pathology, and organ weights nor any noteworthy macroscopic or microscopic findings. This supports the safety of LNFP-I/2 '-FL for its intended uses in food.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available